Form 4: Century Therapeutics CEO's Tax-Related Stock Sale

Century Therapeutics' President and CEO, Brent Pfeiffenberger, disposed of 463 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Brent Pfeiffenberger, President and CEO, and a Director of Century Therapeutics, Inc. (IPSC), reported a transaction on December 10, 2025.
• The transaction involved the disposition of 463 shares of common stock.
• These shares were withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• The price per share for the disposition was $0.526.
• Following this transaction, Pfeiffenberger beneficially owns 3,270,990 shares of common stock directly.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This transaction is a non-discretionary 'sell to cover' for tax purposes related to RSU vesting, which is a routine event and does not reflect a voluntary decision by management to sell shares based on their outlook for the company.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

Transactions involving the disposition of shares to cover tax withholding obligations upon the vesting of restricted stock units are a routine and common occurrence for executives receiving equity compensation across all industries. This is a standard mechanism for managing tax liabilities associated with equity awards.

Comparison to Industry Standards

• The 'sell to cover' mechanism for tax withholding on RSU vesting is a standard practice in executive compensation across publicly traded companies, aligning with typical industry compensation structures.
• The reported transaction volume of 463 shares is relatively small compared to the total beneficial ownership of 3,270,990 shares, which is typical for tax-related dispositions that aim to cover only the immediate tax liability.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence or a significant reduction in their stake.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary transaction where shares were disposed of solely to cover tax withholding obligations upon the vesting of restricted stock units. It does not indicate a change in the reporting person's investment thesis or confidence in Century Therapeutics. Therefore, it provides no new fundamental information to alter an existing investment recommendation, warranting a 'hold' stance based on this specific filing.

Keywords

Century Therapeutics, IPSC, Form 4, Insider Transaction, Stock Sale, RSU Vesting, Tax Withholding, Brent Pfeiffenberger